Related Experiment Videos
Haemophilias: advances towards genetic engineering replacement therapy
G Emilien1, J M Maloteaux, C Penasse
1Laboratory of Pharmacology, Université Catholique de Louvain, Belgium. GEmilien@aol.com
Clinical and Laboratory Haematology
|April 25, 2001
Summary
Gene therapy shows promise for hemophilia A and B by using viral vectors to deliver functional genes for factor VIII and factor IX. Further research aims to improve expression persistence and reduce immune responses for clinical trials.
Area of Science:
- Genetics
- Molecular Biology
- Gene Therapy
Background:
- Hemophilia A and B are X-linked recessive disorders primarily affecting males.
- Genes for factor VIII and factor IX are located on the X chromosome (Xq28 and Xq27.1).
- Factor VIII gene: 186 kb DNA, 9 kb exon, ~9 kb mRNA. Factor IX gene: 34 kb, 8 exons, 1.6 kb mRNA.
Purpose of the Study:
- To explore the potential of gene therapy for treating hemophilia A and B.
- To evaluate ex vivo and in vivo gene modification approaches.
- To assess the efficacy of viral vectors in preclinical models.
Main Methods:
- Gene therapy via ex vivo (isolated cells) or in vivo (target tissue) modification.
- Utilizing retroviral and adenovirus-based vectors for gene delivery.
- Testing in preclinical models such as mice and hemophilic dogs.
Main Results:
- Clinically relevant levels of human factor VIII achieved in animal models.
- Demonstrated feasibility of gene therapy for hemophilia treatment.
- Identified challenges in gene expression persistence and immunological responses.
Conclusions:
- Gene therapy holds significant potential for treating hemophilia A and B.
- Improved viral vectors have shown efficacy in preclinical studies.
- Further advancements are needed to optimize expression and minimize immune reactions before human clinical trials.